/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte Corporation (INCY), headquartered in Wilmington, Delaware, discovers, develops, and commercializes therapeutics for hematology/oncology, as well as inflammation and autoimmunity areas. Valued at $16.8 billion by market cap, the company follows science to find solutions for patients with unmet medical needs. The global biopharmaceutical company is expected to announce its fiscal third-quarter earnings for 2025 before the market opens on Tuesday, Oct. 28.
Ahead of the event, analysts expect INCY to report a profit of $1.38 per share on a diluted basis, up 89% from $0.73 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing the forecast on two other occasions.